Perth, Western Australia, Oct. 27, 2026 (GLOBE NEWSWIRE) —                                                                     

SEPTEMBER 2026 QUARTER REPORT

Perseus delivers another strong quarter, ending with cash & bullion of US$900 million

Perth, Western Australia/ October 27, 2026/ Perseus Mining Limited (“Perseus” or the “Company”) (TSX & ASX: PRU) reports on its activities for the three months’ period ended on September 30, 2026 (the “Quarter”). Below is a summary of the release. The full report is available at www.perseusmining.com www.sedarplus.ca and www.asx.com.au

Overview

  • Group TRIFR 1.01 with Nyanzaga Gold Project (NGP) achieving 10.9 million worked hours LTI free
  • Q1 FY27 Group production exceeds plan with 92,551 ounces of gold at an All-In Site Costs (AISC) of US$2,035 per ounce
  • Average cash margin of US$1,846/oz of gold produced, delivering notional operating cashflow of US$171 million
  • Yaouré CMA Underground achieves commercial production
  • NGP reached 88.4% overall project progress, and development remains on track for first production by January 2027
  • Cash and bullion of US$900 million, plus liquid listed securities valued at US$338 million

FY27 Outlook

With production plans exceeded for Q1 FY27, Perseus remains on track for production and AISC guidance for June 2027 Financial Year (FY27) of 420,000 – 480,000 ounces at US$1,835 – 2,070 per ounce.

Key operating indicators and highlights for the September 2026 quarter (Q1 FY27) include:

Table 1: Group Quarterly Performance

PERFORMANCE INDICATOR  UNIT  DECEMBER 2025
QUARTER
MARCH 2026 
QUARTER 
JUNE 2026 
QUARTER 
SEPTEMBER 2026 
QUARTER3 
Gold recovered Ounces  88,8881 107,1441 109,0131 92,551
Production Cost US$/ounce  1,3622 1,2382 1,3402 1,472
All-In Site Cost (AISC) US$/ounce  1,8002 1,7482 1,9412 2,035
All in Sustaining Cost US$/ounce 1,8972 1,6042 1,8482 1,855
Gold sales Ounces  86,6071 96,2601 114,5671 99,661
Average sales price US$/ounce  3,4372 4,1432 4,0862 3,881
Notional Cashflow US$ million  1452 2522 2162 171
  1. Includes the CMA Underground gold produced and sold for the quarter before commercial production was achieved. Commercial production for CMA Underground was achieved on 1 July 2026.  
  2. Excludes CMA Underground production cost, gold produced, AISC, Average sales price and Notional Cashflow as the related cash costs are capitalised until commercial production was achieved.
  3. All metrics include CMA Underground following commercial production achieved on 1 July 2026.

Perseus’s Managing Director and CEO Craig Jones said:

“The September Quarter was a solid start to FY27, with all three operations performing and on track for our full year guidance. The CMA Underground has achieved commercial production and our Nyanzaga project is progressing to completion with an outstanding safety record, remaining on budget and on schedule. Our balance sheet remains strong and debt-free, to fund our growth objectives while continuing to deliver meaningful returns to shareholders through our buy-back and the upcoming Special Distribution. I want to thank our employees and contractors for their continued commitment across our sites.

Looking ahead, we expect production to build through the second half of the year as Yaouré’s CMA continues to increase production and Edikan accesses higher grades in the Nkosuo pit along with Nyanzaga commencing operation, positioning Perseus for a transformational year”.

Conference Call Perseus will host investor webinar and conference call to discuss its September 2026 Quarterly Results, at 9.00am AEDT today (27 October 2026). Register for the webinar at:
https://us02web.zoom.us/webinar/register/WN_5JPqtLq5QVOV1wqjG1Mn1g

A recording of the conference call will be made available via Perseus’s website at www.perseusmining.com.

GROUP GOLD PRODUCTION AND COST GUIDANCE

Perseus remains on track to deliver group gold production and AISC for the 2027 financial year as shown in Table 6 below.

Table 6: Production and AISC Guidance

PARAMETER UNITS SEPTEMBER 2026 
QUARTER (ACTUAL)
2027 FINANCIAL YEAR
FORECAST
Yaouré Gold Mine    
Production Ounces   36,648 150,000 – 170,000
All-in Site Cost (1) US$ per ounce $ 2,393 $1,955 – $2,205
Edikan Gold Mine    
Production Ounces   35,830 150,000 – 170,000
All-in Site Cost (1) US$ per ounce $ 1,738 $1,700 – $1,920
Sissingué Gold Mine    
Production Ounces   20,073 65,000 – 85,000
All-in Site Cost (1) US$ per 0unce $ 1,913 $1,865 – $2,105
Nyanzaga Gold Mine      
Production (2) Ounces   – ~55,000
PERSEUS GROUP      
Production Ounces   92,551 420,000 – 480,000
All-in Site Cost (1) US$ per ounce $ 2,035 $1,835 – $2,070

Notes

  1. Cost guidance is based on a gold price assumption of $4,000 per ounce and Government royalty rates of 8% in Côte d’Ivoire and 11% (applicable at $4,000 per ounce) in Ghana. Group AISC and has only been calculated based on the three operating mines.
  2. Nyanzaga production guidance is based on FID as released in April 2025 – Refer ASX Release – Perseus mining proceeds with development of the Nyanzaga Gold Project. Further guidance for Nyanzaga will be provided in Q3 FY27. All operating costs for Nyanzaga are capitalised until Commercial Production planned for Q4 FY27.

DECEMBER 2026 QUARTER EVENTS & ANNOUNCEMENTS

  • 27 October – September 2026 Quarterly Report & Webinar
  • 5 November – Macquarie WA Forum
  • 9 November – UBS Australasia conference
  • 30 November – Annual General Meeting

Competent Person Statement

All production targets referred to in this release are underpinned by estimated Ore Reserves which have been prepared by Competent Persons in accordance with the requirements of the JORC Code.

The information in this report that relates to the Mineral Resources and Ore Reserve was updated by the Company in a market announcement “Perseus Mining updates Mineral Resources and Ore Reserves” released on 26 August 2026. The Company confirms that all material assumptions underpinning those estimates and the production targets, or the forecast financial information derived therefrom, in that market release continue to apply and have not materially changed.

The Company confirms that the material assumptions underpinning the estimates of Ore Reserves described in “Technical Report — Edikan Gold Mine, Ghana” dated 6 April 2022, “Technical Report — Yaouré Gold Project, Côte d’Ivoire” dated 18 December 2023, “Technical Report — Sissingué Gold Project, Côte d’Ivoire” dated 29 May 2015, and “Technical Report — Nyanzaga Gold Project, Tanzania” dated 10 June 2025 continue to apply.

Caution Regarding Forward Looking Information:

This report contains forward-looking information which is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management of the Company believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Assumptions have been made by the Company regarding, among other things: the price of gold, continuing commercial production at the Yaouré Gold Mine, the Edikan Gold Mine and the Sissingué Gold Mine without any major disruption, development of a mine at Nyanzaga, the receipt of required governmental approvals, the accuracy of capital and operating cost estimates, the ability of the Company to operate in a safe, efficient and effective manner and the ability of the Company to obtain financing as and when required and on reasonable terms. Readers are cautioned that the foregoing list is not exhaustive of all factors and assumptions which may have been used by the Company. Although management believes that the assumptions made by the Company and the expectations represented by such information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate. Forward-looking information involves known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any anticipated future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others, the actual market price of gold, the actual results of current exploration, the actual results of future exploration, changes in project parameters as plans continue to be evaluated, as well as those factors disclosed in the Company’s publicly filed documents. Readers should not place undue reliance on forward-looking information. Perseus does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

This market announcement was authorised for release by Craig Jones, Managing Director and CEO

SX/TSX CODE: PRU
CAPITAL STRUCTURE:
Ordinary shares: 1,326,111,555
Performance rights: 7,286,920
REGISTERED OFFICE:
Level 2
437 Roberts Road
Subiaco WA 6008
Telephone: +61 8 6144 1700
www.perseusmining.com
DIRECTORS:
Rick Menell
Non-Executive Chairman
Craig Jones
Managing Director & CEO
Amber Banfield
Non-Executive Director
Elissa Cornelius
Non-Executive Director
Dan Lougher
Non-Executive Director
John McGloin
Non-Executive Director
Tommy McKeith
Non-Executive Director
Jim Rutherford
Non-Executive Director
CONTACTS:
Craig Jones
Managing Director & CEO
craig.jones@perseusmining.com
Stephen Forman
Investor Relations
+61 484 036 681
stephen.forman@perseusmining.com
Nathan Ryan
Media
+61 420 582 887
nathan.ryan@nwrcommunications.com.au

Attachment

Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026

Mont-Saint-Guibert, Belgium – October 26, 2026, 10:05 pm CET / 5:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the third quarter of 2026 on Thursday, November 5, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30 pm CET / 4:30 pm ET.

A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah’s Q3 2026 Earnings Call Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Nyxoah’s Q3 2026 Earnings Call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study in 2024 and received approval from the FDA in August 2025, with the treatment of CCC patients included in the warning section of our indications for use.

For more information, please visit http://www.nyxoah.com.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company’s commercialization strategy in the U.S. market; the Company’s results of operations, financial condition, liquidity, performance, prospects, growth, future revenue, future operating expenses, future gross margins and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2026 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah

Loïc Moreau, Interim CFO

IR@nyxoah.com

Rémi Renard, Head of Investor Relations & Corporate Communication

IR@nyxoah.com

Attachment

Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026

Mont-Saint-Guibert, Belgium – October 26, 2026, 10:05 pm CET / 5:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the third quarter of 2026 on Thursday, November 5, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30 pm CET / 4:30 pm ET.

A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah’s Q3 2026 Earnings Call Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Nyxoah’s Q3 2026 Earnings Call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study in 2024 and received approval from the FDA in August 2025, with the treatment of CCC patients included in the warning section of our indications for use.

For more information, please visit http://www.nyxoah.com.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company’s commercialization strategy in the U.S. market; the Company’s results of operations, financial condition, liquidity, performance, prospects, growth, future revenue, future operating expenses, future gross margins and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2026 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah

Loïc Moreau, Interim CFO

IR@nyxoah.com

Rémi Renard, Head of Investor Relations & Corporate Communication

IR@nyxoah.com

Attachment

CINCINNATI, Ohio, Oct. 26, 2026 (GLOBE NEWSWIRE) — Onconetix, Inc. (Nasdaq: ONCO) (the “Company”), today announced that its Board of Directors has approved a one-for-ten (1-for-10) reverse stock split of the Company’s outstanding common stock. The reverse split is expected to become effective at 12:01 a.m. Eastern Time on November 6, 2026. The Company’s common stock has been assigned a new CUSIP number, 68237Q500, in connection with the reverse stock split.

Following the reverse split, every ten (10) shares of Onconetix common stock will be automatically exchanged into one share of common stock. The Company’s common stock will continue to trade on Nasdaq under the symbol “ONCO”.

The reverse split will reduce the number of outstanding shares of common stock from approximately 5,886,774 shares outstanding as of October 21, 2026 to approximately 588,677 shares, before giving effect to adjustments resulting from the treatment of fractional shares. The reverse stock split will not change the number of authorized shares of common stock, which will remain at 250,000,000 shares, or the par value of the Company’s common stock, which will remain at $0.00001 per share. No fractional shares will be issued in connection with the reverse split. Stockholders who would otherwise be entitled to receive fractional shares will instead receive cash payments in lieu of such fractional shares.

The reverse stock split will be effected simultaneously for all outstanding shares of the Company’s common stock and will affect all of the Company’s stockholders uniformly. The reverse stock split will not affect any stockholder’s percentage ownership interest in the Company, except to the extent that a stockholder would otherwise be entitled to receive a fractional share for which cash will be paid in lieu thereof. The reverse stock split will not affect the par value of the Company’s common stock and will also not affect the number of authorized shares or par value of our preferred stock. The rights and privileges of the holders of the common stock will be unaffected by the reverse stock split. Proportionate adjustments will be made, as applicable and in accordance with their respective terms, to the exercise or conversion prices and the number of shares issuable under the Company’s outstanding options, warrants, convertible securities and equity incentive plans.

About Onconetix, Inc.

Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative oncology solutions. Onconetix owns Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the IVDR, which it anticipates will be marketed in the U.S. as a lab developed test through its license agreement with Labcorp. For more information, visit www.onconetix.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Onconetix’s current expectations and actual results could differ materially. Investors should read the risk factors set forth in Onconetix’s Annual Report on Form 10-K filed with the SEC on March 13, 2026, and periodic reports filed with the SEC on or after the date thereof. All forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof. Onconetix does not undertake an obligation to update or revise any forward-looking statement except as required by applicable law.

Investor and Media Contact:

Onconetix, Inc.

201 E. Fifth Street, Suite 1900

Cincinnati, OH 45202

Phone: (513) 620-4101

Email: investors@onconetix.com

CINCINNATI, Ohio, Oct. 26, 2026 (GLOBE NEWSWIRE) — Onconetix, Inc. (Nasdaq: ONCO) (the “Company”), today announced that its Board of Directors has approved a one-for-ten (1-for-10) reverse stock split of the Company’s outstanding common stock. The reverse split is expected to become effective at 12:01 a.m. Eastern Time on November 6, 2026. The Company’s common stock has been assigned a new CUSIP number, 68237Q500, in connection with the reverse stock split.

Following the reverse split, every ten (10) shares of Onconetix common stock will be automatically exchanged into one share of common stock. The Company’s common stock will continue to trade on Nasdaq under the symbol “ONCO”.

The reverse split will reduce the number of outstanding shares of common stock from approximately 5,886,774 shares outstanding as of October 21, 2026 to approximately 588,677 shares, before giving effect to adjustments resulting from the treatment of fractional shares. The reverse stock split will not change the number of authorized shares of common stock, which will remain at 250,000,000 shares, or the par value of the Company’s common stock, which will remain at $0.00001 per share. No fractional shares will be issued in connection with the reverse split. Stockholders who would otherwise be entitled to receive fractional shares will instead receive cash payments in lieu of such fractional shares.

The reverse stock split will be effected simultaneously for all outstanding shares of the Company’s common stock and will affect all of the Company’s stockholders uniformly. The reverse stock split will not affect any stockholder’s percentage ownership interest in the Company, except to the extent that a stockholder would otherwise be entitled to receive a fractional share for which cash will be paid in lieu thereof. The reverse stock split will not affect the par value of the Company’s common stock and will also not affect the number of authorized shares or par value of our preferred stock. The rights and privileges of the holders of the common stock will be unaffected by the reverse stock split. Proportionate adjustments will be made, as applicable and in accordance with their respective terms, to the exercise or conversion prices and the number of shares issuable under the Company’s outstanding options, warrants, convertible securities and equity incentive plans.

About Onconetix, Inc.

Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative oncology solutions. Onconetix owns Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the IVDR, which it anticipates will be marketed in the U.S. as a lab developed test through its license agreement with Labcorp. For more information, visit www.onconetix.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Onconetix’s current expectations and actual results could differ materially. Investors should read the risk factors set forth in Onconetix’s Annual Report on Form 10-K filed with the SEC on March 13, 2026, and periodic reports filed with the SEC on or after the date thereof. All forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof. Onconetix does not undertake an obligation to update or revise any forward-looking statement except as required by applicable law.

Investor and Media Contact:

Onconetix, Inc.

201 E. Fifth Street, Suite 1900

Cincinnati, OH 45202

Phone: (513) 620-4101

Email: investors@onconetix.com

DAYTONA BEACH, Fla., Oct. 26, 2026 (GLOBE NEWSWIRE) — Brown & Brown, Inc. (NYSE:BRO) (the “Company”) announced its unaudited financial results for the third quarter of 2026.

For the third quarter ended September 30, 2026, the Company achieved:

  • Total revenues of $1.7 billion, increasing $119 million, or 7.4%, compared to the third quarter of the prior year, with growth of Organic Revenue of 1.2% and growth of Organic Revenue with Contingents of 1.5%.
  • Income before income taxes of $320 million, increasing 2.9%, with Income Before Income Taxes Margin of 18.6%, compared to 19.4% in the third quarter of the prior year.
  • EBITDAC – Adjusted of $597 million, increasing 1.7%, with EBITDAC Margin – Adjusted of 34.6%, compared to 36.6% in the third quarter of the prior year.
  • Net income attributable to the Company of $240 million, increasing $13 million, or 5.7%, compared to the third quarter of the prior year.
  • Diluted net income per share of $0.67, a decrease of 1.5%, with Diluted Net Income Per Share – Adjusted increasing to $1.07, or 1.9%, each compared to the third quarter of the prior year.

For the nine months ended September 30, 2026, the Company achieved:

  • Total revenues of $5.3 billion, increasing $1.0 billion, or 23.4%, compared to the same period in 2025, with growth of Organic Revenue of 0.3% and growth of Organic Revenue with Contingents of 1.5%.
  • Income before income taxes of $1.2 billion, increasing 17.6%, with Income Before Income Taxes Margin of 23.3%, compared to 24.4% in the same period in 2025.
  • EBITDAC – Adjusted of $1.9 billion, increasing 20.9%, with EBITDAC Margin – Adjusted of 36.3%, compared to 37.1% in the same period in 2025.
  • Net income attributable to the Company of $954 million, increasing $164 million, or 20.8%, compared to the same period in 2025.
  • Diluted net income per share of $2.57, flat compared to the same period in 2025, with Diluted Net Income Per Share – Adjusted increasing to $3.52, or 5.7%, compared to the same period in 2025.

J. Powell Brown, president and chief executive officer of the Company, noted, “The third quarter reflected the incredible efforts of our teammates to win more customers in spite of a challenging rate environment. Our capabilities were broadly enhanced by the addition of approximately 5,000 new teammates from Accession, just over a year ago.”

             
Reconciliation of Commissions and Fees
to Organic Revenue and Organic Revenue with Contingents
(in millions, unaudited)

             
    Three Months Ended September 30,     Nine Months Ended September 30,  
    2026     2025     2026     2025  
Commissions and fees   $ 1,700     $ 1,550     $ 5,234     $ 4,183  
Contingents     (80 )     (73 )     (262 )     (161 )
Core commissions and fees   $ 1,620     $ 1,477     $ 4,972     $ 4,022  
Acquisitions     (156 )           (985 )      
Dispositions           (13 )           (20 )
Foreign Currency Translation           (1 )           19  
Litigation-Related Impact           (16 )           (44 )
Organic Revenue   $ 1,464     $ 1,447     $ 3,987     $ 3,977  
Organic Revenue growth     17             10        
Organic Revenue growth %     1.2 %           0.3 %      
                         
Organic Contingents   $ 79     $ 73     $ 213     $ 161  
Organic Revenue with Contingents     1,543       1,520       4,200       4,138  
Organic Revenue with Contingents growth   $ 23           $ 62        
Organic Revenue with Contingents growth %     1.5 %           1.5 %      
                             

See information regarding non-GAAP measures presented later in this press release.

                         
Reconciliation of Diluted Net Income Per Share to
Diluted Net Income Per Share – Adjusted
(unaudited)

                         
    Three Months Ended
September 30,
    Change     Nine Months Ended
September 30,
    Change  
    2026     2025     $     %     2026     2025     $     %  
Diluted net income per share(1)   $ 0.67     $ 0.68     $ (0.01 )     (1.5 %)   $ 2.57     $ 2.57     $ —       (— %)
Change in estimated acquisition earn-out payables     0.06       0.02       0.04             (0.02 )     0.04       (0.06 )      
(Gain)/loss on disposal     —       —       —             —       —       —        
Acquisition/Integration Costs     0.09       0.13       (0.04 )           0.21       0.22       (0.01 )      
Amortization     0.25       0.20       0.05             0.76       0.48       0.28        
Mark-to-market of escrow liability(2)     —       0.02       (0.02 )           —       0.02       (0.02 )      
Diluted Net Income Per Share – Adjusted   $ 1.07     $ 1.05     $ 0.02       1.9 %   $ 3.52     $ 3.33     $ 0.19       5.7 %
                                                                 

(1) The calculation of diluted net income per share for the three and nine months ended September 30, 2026 (a) excludes the mark-to-market of escrow liability and (b) includes the escrowed shares within the Company’s diluted weighted average number of shares, in each case in accordance with Accounting Standards Codification Topic 260 — Earnings Per Share (“ASC 260”), which requires this treatment in periods where the combined effect of these adjustments is accretive to earnings.

(2) No adjustment for the mark-to-market of escrow liability was made to Diluted Net Income Per Share – Adjusted for the three or nine months ended September 30, 2026 as the calculation of diluted net income per share for these periods already excludes the mark-to-market of escrow liability in accordance with ASC 260.

See information regarding non-GAAP measures presented later in this press release.

             
Reconciliation of Income Before Income Taxes to EBITDAC and
EBITDAC – Adjusted and Income Before Income Taxes Margin(1) to
EBITDAC Margin and EBITDAC Margin – Adjusted
(in millions, unaudited)

             
    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2026     2025(2)     2026     2025(2)  
Total revenues   $ 1,725     $ 1,606     $ 5,302     $ 4,295  
Income before income taxes   $ 320     $ 311     $ 1,235     $ 1,050  
Income Before Income Taxes Margin(1)     18.6 %     19.4 %     23.3 %     24.4 %
Amortization     110       93       337       196  
Depreciation     18       14       53       37  
Interest     100       100       299       197  
Change in estimated acquisition earn-out payables     27       11       (7 )     18  
EBITDAC   $ 575     $ 529     $ 1,917     $ 1,498  
EBITDAC Margin     33.3 %     32.9 %     36.2 %     34.9 %
(Gain)/loss on disposal     —       —       —       1  
Acquisition/Integration Costs     36       50       93       87  
Mark-to-market of escrow liability     (14 )     8       (83 )     8  
EBITDAC – Adjusted   $ 597     $ 587     $ 1,927     $ 1,594  
EBITDAC Margin – Adjusted     34.6 %     36.6 %     36.3 %     37.1 %
                                 

(1) “Income Before Income Taxes Margin” is defined as income before income taxes divided by total revenues.

(2) 2025 amounts reflect the positive impact of approximately $29 million and $42 million for the three and nine months ended September 30,2025, respectively, of interest income earned from the proceeds of the Company’s follow-on common stock offering and senior notes issuance in June 2025, held in preparation for the closing of the Company’s acquisition of RSC Topco, Inc.

See information regarding non-GAAP measures presented later in this press release.

             
Brown & Brown, Inc.
Consolidated Statements of Income
(in millions, except per share data; unaudited)
             
    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
REVENUES                        
Commissions and fees   $ 1,700     $ 1,550     $ 5,234     $ 4,183  
Investment and other income     25       56       68       112  
Total revenues     1,725       1,606       5,302       4,295  
EXPENSES                        
Employee compensation and benefits     857       793       2,602       2,116  
Other operating expenses     307       276       866       672  
(Gain)/loss on disposal     —       —       —       1  
Amortization     110       93       337       196  
Depreciation     18       14       53       37  
Interest     100       100       299       197  
Change in estimated acquisition earn-out payables     27       11       (7 )     18  
Mark-to-market of escrow liability     (14 )     8       (83 )     8  
Total expenses     1,405       1,295       4,067       3,245  
Income before income taxes     320       311       1,235       1,050  
Income taxes     79       82       278       251  
Net income before non-controlling interests     241       229       957       799  
Less: Net income attributable to non-controlling interests     1       2       3       9  
Net income attributable to the Company   $ 240     $ 227     $ 954     $ 790  
Net income per share:                        
Basic   $ 0.73     $ 0.68     $ 2.87     $ 2.59  
Diluted   $ 0.67     $ 0.68     $ 2.57     $ 2.57  
Weighted average number of shares outstanding:                        
Basic     325       331       328       302  
Diluted     330       332       334       304  

             
Brown & Brown, Inc.
Consolidated Balance Sheets
(in millions, except per share data, unaudited)
             
    September 30,
2026
    December 31,
2025
 
ASSETS            
Current assets:            
Cash and cash equivalents   $ 1,099     $ 1,079  
Fiduciary cash     2,442       2,471  
Commission, fees, and other receivables     1,515       1,438  
Fiduciary receivables     1,234       1,515  
Reinsurance recoverable     665       647  
Prepaid reinsurance premiums     808       980  
Other current assets     498       484  
Total current assets     8,261       8,614  
Fixed assets, net     389       367  
Operating lease assets     304       269  
Goodwill     15,188       15,087  
Amortizable intangible assets, net     4,468       4,906  
Other assets     838       748  
Total assets   $ 29,448     $ 29,991  
LIABILITIES AND EQUITY            
Current liabilities:            
Fiduciary liabilities   $ 3,676     $ 3,986  
Losses and loss adjustment reserve     687       671  
Unearned premiums     903       1,053  
Accounts payable     709       990  
Accrued expenses and other liabilities     844       875  
Current portion of long-term debt     413       719  
Total current liabilities     7,232       8,294  
Long-term debt less unamortized discount and debt issuance costs     7,346       6,894  
Operating lease liabilities     279       243  
Deferred income taxes, net     937       815  
Other liabilities     1,053       1,172  
Equity:            
Common stock, par value $0.10 per share; authorized 560 shares; issued 359 shares and outstanding 327 shares at 2026, issued 357 shares and outstanding 336 shares at 2025     36       36  
Additional paid-in capital     6,253       6,160  
Treasury stock, at cost 32 shares at 2026 and 21 shares at 2025     (1,604 )     (848 )
Accumulated other comprehensive income     124       210  
Non-controlling interests     18       26  
Retained earnings     7,774       6,989  
Total equity     12,601       12,573  
Total liabilities and equity   $ 29,448     $ 29,991  

       
Brown & Brown, Inc.
Consolidated Statements of Cash Flows
(in millions, unaudited)
       
    Nine Months Ended
September 30,
 
    2026     2025  
Cash flows from operating activities:            
Net income before non-controlling interests   $ 957     $ 799  
Adjustments to reconcile net income before non-controlling interests to net cash provided by operating activities:            
Amortization     337       196  
Depreciation     53       37  
Non-cash stock-based compensation     72       76  
Change in estimated acquisition earn-out payables     (7 )     18  
Mark-to-market of escrow liability     (83 )     8  
Deferred income taxes     158       18  
Net loss on sales/disposals of investments, businesses, fixed assets and customer accounts     —       2  
Payments on acquisition earn-outs in excess of original estimated payables     (42 )     (1 )
Other     10       5  
Changes in operating assets and liabilities, net of effect from acquisitions and divestitures:            
Commissions, fees and other receivables (increase)/decrease     (100 )     (59 )
Reinsurance recoverable (increase)/decrease     (18 )     1,190  
Prepaid reinsurance premiums (increase)/decrease     172       8  
Other assets (increase)/decrease     (87 )     (23 )
Losses and loss adjustment reserve increase/(decrease)     16       (1,188 )
Unearned premiums increase/(decrease)     (153 )     15  
Accounts payable increase/(decrease)     (107 )     (95 )
Accrued expenses and other liabilities increase/(decrease)     (63 )     (41 )
Other liabilities increase/(decrease)     25       41  
Net cash provided by operating activities     1,140       1,006  
Cash flows from investing activities:            
Additions to fixed assets     (77 )     (48 )
Payments for businesses acquired, net of cash acquired     (41 )     (7,659 )
Proceeds from sales of businesses, fixed assets and customer accounts     3       10  
Other investing activities     (10 )     (4 )
Net cash used in investing activities     (125 )     (7,701 )
Cash flows from financing activities:            
Fiduciary receivables and liabilities, net     (14 )     (145 )
Payments on acquisition earn-outs     (199 )     (77 )
Proceeds from long-term debt     —       4,192  
Payments on long-term debt     (34 )     (206 )
Deferred debt issuance costs     (3 )     (37 )
Borrowings on revolving credit facility     225       450  
Payments on revolving credit facility     (50 )     (500 )
Proceeds from issuance of common stock, net of expenses     —       4,315  
Issuances of common stock for employee stock benefit plans     47       43  
Repurchase shares to fund tax withholdings for non-cash stock-based compensation     (30 )     (42 )
Purchase of treasury stock     (750 )     —  
Cash dividends paid     (169 )     (137 )
Other financing activities     (12 )     (5 )
Net cash (used in) provided by financing activities     (989 )     7,851  
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash inclusive of fiduciary cash     (29 )     66  
Net (decrease) increase in cash, cash equivalents and restricted cash inclusive of fiduciary cash     (3 )     1,222  
Cash, cash equivalents and restricted cash inclusive of fiduciary cash at beginning of period     3,815       2,502  
Cash, cash equivalents and restricted cash inclusive of fiduciary cash at end of period   $ 3,812     $ 3,724  
                 

Conference call, webcast and slide presentation

A conference call to discuss the results of the third quarter of 2026 will be held on Tuesday, October 27, 2026, at 8:00 AM (EDT). The Company may refer to a slide presentation during its conference call. You can access the webcast and the slides from the “Investor Relations” section of the Company’s website at bbrown.com.

About Brown & Brown

Brown & Brown, Inc. (NYSE: BRO) is a leading insurance brokerage firm delivering comprehensive and customized insurance solutions and specialization since 1939. With a global presence spanning 700+ locations and a team of approximately 23,000 professionals, we are dedicated to delivering scalable, innovative strategies for our customers at every step of their growth journey. Learn more at BBrown.com.

Forward-looking statements

This press release may contain certain statements relating to future results which are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created by those laws. You can identify these statements by forward-looking words such as “may,” “will,” “should,” “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan” and “continue” or similar words. We have based these statements on our current expectations about potential future events. Although we believe the expectations expressed in the forward-looking statements included in this press release are based upon reasonable assumptions within the bounds of our knowledge of our business, a number of factors could cause actual results to differ materially from those expressed in any forward-looking statements, whether oral or written, made by us or on our behalf. Many of these factors have previously been identified in filings or statements made by us or on our behalf. Important factors which could cause our actual results to differ, possibly materially from the forward-looking statements in this press release include but are not limited to the following items: the Company’s determination as it finalizes its financial results for the third quarter of 2026 that its financial results differ from the current preliminary unaudited numbers set forth herein; risks with respect to the acquisition of RSC Topco, Inc. (“Accession”) (the “Transaction”); the possibility that the anticipated benefits, including any anticipated cost savings and strategies, of the Transaction are not realized when expected or at all; risks related to the financing of the Transaction, including that financing the Transaction resulted in an increase in the Company’s indebtedness; risks relating to the financial information related to Accession; the risk that certain assumptions the Company has made relating to the Transaction prove to be materially inaccurate; risks related to Accession’s business, including underwriting risk in connection with certain captive insurance companies; the inability to hire, retain and develop qualified employees, as well as the loss of any of our executive officers or other key employees; a cybersecurity attack or any other interruption in information technology and/or data security that may impact our operations or the operations of third parties that support us; acquisition-related risks that could negatively affect the success of our growth strategy, including the possibility that we may not be able to successfully identify suitable acquisition candidates, complete acquisitions, successfully integrate acquired businesses into our operations and expand into new markets; risks related to our international operations, which may result in additional risks or require more management time and expense than our domestic operations to achieve or maintain profitability; the requirement for additional resources and time to adequately respond to dynamics resulting from rapid technological change, including the increasing use of artificial intelligence and robotic processing automation; the loss of or significant change to any of our insurance company or intermediary relationships, which could result in loss of capacity to write business, additional expense, loss of market share or material decrease in our commissions; the effect of natural disasters on our Contingents, insurer capacity or claims expenses within our capitalized captive insurance facilities; adverse economic conditions, political conditions, outbreaks of war, disasters, or regulatory changes in states or countries where we have a concentration of our business; the inability to maintain our culture or a significant change in management, management philosophy or our business strategy; fluctuations in our commission revenue as a result of factors outside of our control; the effects of significant or sustained inflation or higher interest rates; claims expense resulting from the limited underwriting risk associated with our participation in captive insurance facilities; risks associated with our automobile and recreational vehicle finance and incentives dealer services (“F&I”) businesses; changes in, or the termination of, certain programs administered by the U.S. federal government from which we derive revenues; the limitations of our system of disclosure and internal controls and procedures in preventing errors or fraud, or in informing management of all material information in a timely manner; our reliance on vendors and other third parties to perform key functions of our business operations and provide services to our customers; the significant control certain shareholders have; changes in data privacy and protection laws and regulations or any failure to comply with such laws and regulations; improper disclosure of confidential information; our ability to comply with non-U.S. laws, regulations and policies; the potential adverse effect of certain actual or potential claims, regulatory actions or proceedings on our businesses, results of operations, financial condition or liquidity; uncertainty in our business practices and compensation arrangements with insurance carriers due to potential changes in regulations; regulatory changes that could reduce our profitability or growth by increasing compliance costs, technology compliance, restricting the products or services we may sell, the markets we may enter, the methods by which we may sell our products and services, or the prices we may charge for our services and the form of compensation we may accept from our customers, carriers and third parties; increasing scrutiny and changing laws or competing expectations from regulators, investors and customers with respect to our environmental, social and governance practices and disclosure; a decrease in demand for liability insurance as a result of tort reform legislation; our failure to comply with any covenants contained in our debt agreements; the possibility that covenants in our debt agreements could prevent us from engaging in certain potentially beneficial activities; fluctuations in foreign currency exchange rates; a downgrade to our corporate credit rating, the credit ratings of our outstanding debt or other market speculation; future sales or other dilution of our equity could adversely affect the market price of our common stock; changes in the U.S.-based credit markets that might adversely affect our business, results of operations and financial condition; changes in current U.S. or global economic conditions, including an extended slowdown in the markets in which we operate; disintermediation within the insurance industry, including increased competition from insurance companies, technology companies and the financial services industry, as well as the shift away from traditional insurance markets; conditions that result in reduced insurer capacity; quarterly and annual variations in our commissions that result from the timing of policy renewals and the net effect of new and lost business production; intangible asset risk, including the possibility that our goodwill may become impaired in the future; changes in our accounting estimates and assumptions; other risks and uncertainties as may be detailed from time to time in our public announcements and Securities and Exchange Commission (“SEC”) filings; and other factors that the Company may not have currently identified or quantified. Assumptions as to any of the foregoing, and all statements, are not based upon historical fact, but rather reflect our current expectations concerning future results and events. Forward-looking statements that we make or that are made by others on our behalf are based upon a knowledge of our business and the environment in which we operate, but because of the factors listed above, among others, actual results may differ from those in the forward-looking statements. Consequently, these cautionary statements qualify all of the forward-looking statements we make herein. We cannot assure you that the results or developments anticipated by us will be realized, or even if substantially realized, that those results or developments will result in the expected consequences for us or affect us, our business or our operations in the way we expect. We caution readers not to place undue reliance on these forward-looking statements. All forward-looking statements made herein are made only as of the date of this press release, and the Company does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which the Company hereafter becomes aware.

Non-GAAP supplemental financial information

This press release contains references to “non-GAAP financial measures” as defined in SEC Regulation G, consisting of Organic Revenue, Organic Revenue with Contingents, EBITDAC, EBITDAC Margin, EBITDAC – Adjusted, EBITDAC Margin – Adjusted and Diluted Net Income Per Share – Adjusted. We present these measures because we believe such information is of interest to the investment community and because we believe they provide additional meaningful methods to evaluate the Company’s operating performance from period to period on a basis that may not be otherwise apparent on a GAAP basis due to the impact of certain items that have a high degree of variability, that we believe are not indicative of ongoing performance and that are not easily comparable from period to period. This non-GAAP financial information should be considered in addition to, not in lieu of, GAAP information as of the relevant date. Consistent with Regulation G, a description of such information is provided below, and tabular reconciliations of such items to our most directly comparable GAAP information can be found within this press release as well as in our periodic filings with the SEC.

We view Organic Revenue and Organic Revenue growth (including Organic Revenue with Contingents and its growth) as important indicators when assessing and evaluating our performance on a consolidated basis and for each of our two segments, because they allow us to determine a comparable, but non-GAAP, measurement of revenue growth that is associated with the revenue sources that were a part of our business in both the current and prior year and that are expected to continue in the future. In addition, we believe Diluted Net Income Per Share – Adjusted provides a meaningful representation of our operating performance and improves the comparability of our results between periods by excluding the impact of the change in estimated acquisition earn-out payables, the impact of amortization of intangible assets and certain other non-recurring or infrequently occurring items. We also view EBITDAC, EBITDAC – Adjusted, EBITDAC Margin and EBITDAC Margin – Adjusted as important indicators when assessing and evaluating our performance, as they present more comparable measurements of our operating margins in a meaningful and consistent manner. As disclosed in our most recent proxy statement, we use Organic Revenue growth, Diluted Net Income Per Share – Adjusted and EBITDAC Margin – Adjusted as key performance metrics for our short-term and long-term incentive compensation plans for executive officers and other key employees.

Non-GAAP Revenue Measures

  • Organic Revenue is our core commissions and fees less: (i) the core commissions and fees earned for the first twelve months by newly acquired operations; (ii) divested business (core commissions and fees generated from offices, books of business or niches sold or terminated during the comparable period); (iii) Foreign Currency Translation (as defined below) and (iv) the Litigation-Related Impact. The term “core commissions and fees” excludes profit-sharing contingent commissions (“Contingents”); and therefore, represents the revenues earned directly from specific insurance policies sold and specific fee-based services rendered. Growth of Organic Revenue can be expressed as a dollar amount or a percentage rate.
  • Organic Revenue with Contingents is Organic Revenue plus Organic Contingents (as defined below). Growth of Organic Revenue with Contingents can be expressed as a dollar amount or a percentage rate.

Non-GAAP Earnings Measures

  • EBITDAC is defined as income before interest, income taxes, depreciation, amortization and the change in estimated acquisition earn-out payables.
  • EBITDAC Margin is defined as EBITDAC divided by total revenues.
  • EBITDAC – Adjusted is defined as EBITDAC, excluding (i) (gain)/loss on disposal (as defined below), (ii) Acquisition/Integration Costs (as defined below) and (iii) mark-to-market of escrow liability (as defined below).
  • EBITDAC Margin – Adjusted is defined as EBITDAC – Adjusted divided by total revenues.
  • Diluted Net Income Per Share – Adjusted is defined as diluted net income per share, excluding the after-tax impact of (i) the change in estimated acquisition earn-out payables, (ii) (gain)/loss on disposal, (as defined below), (iii) Acquisition/Integration Costs (as defined below), (iv) mark-to-market of escrow liability (as defined below) in periods wherein the effect of mark-to-market of escrow liability is not dilutive to the Company’s earnings and, therefore, not already excluded from the calculation of diluted net income per share in accordance with ASC 260, and (v) amortization.

Definitions Related to Certain Components of Non-GAAP Measures

  • “Acquisition/Integration Costs” means the acquisition and integration costs (e.g., costs associated with regulatory filings; costs for third-party professional services, including legal, accounting, consulting, financial advisory and due diligence; costs and fees associated with entry into the bridge financing commitment; costs of integrating or streamlining processes and information technology systems, including data migration and system integration; costs associated with optimizing vendor agreements and leased office space, including exit costs related to location combinations; and employment-related costs, including severance payments, costs associated with the transition of certain legacy compensation programs, retention-related compensation expenses, and incentive payments) arising out of our acquisition of Accession and acquisitions previously completed by Accession, which are not considered to be normal, recurring or part of ongoing operations.
  • “Foreign Currency Translation” means the period-over-period impact of foreign currency translation, which is calculated by applying current-year foreign exchange rates to the various functional currencies in our business to our reporting currency of US dollars for the same period in the prior year.
  • “(Gain)/loss on disposal” is a caption on our consolidated statements of income which reflects net proceeds received as compared to the net book value related to sales of books of business and other divestiture transactions.
  • “Mark-to-market of escrow liability” is a caption on our consolidated statements of income which reflects the non-cash change in the fair value associated with certain shares of the Company’s common stock held in escrow. The change is driven by fluctuations in our stock price between the beginning of the period and the end of the period. These escrowed shares represent a portion of the merger consideration payable in connection with our acquisition of Accession. The escrowed shares secure certain indemnification obligations of the Accession equity holders related to businesses that are in run-off or discontinued.
  • “Litigation-Related Impact” means the core commissions and fees attributable to (i) the loss of specifically identified customer accounts and (ii) new business generated in the prior year by certain former employees, in each case in connection with the conduct of a competitor that is the subject of pending litigation in multiple jurisdictions.
  • “Organic Contingents” are Contingents, less (i) Contingents earned for the first twelve months by newly acquired stand-alone operations and (ii) Contingents earned from divested stand-alone operations (Contingents generated from stand-alone operations sold or terminated during the comparable period).

Our industry peers may provide similar supplemental non-GAAP information with respect to one or more of these measures, although they may not use the same or comparable terminology and may not make identical adjustments and, therefore comparability may be limited. This supplemental non-GAAP financial information should be considered in addition to, and not in lieu of, the Company’s condensed consolidated financial statements.

For more information:

R. Andrew Watts
Chief Financial Officer
(386) 239-5770

DAYTONA BEACH, Fla., Oct. 26, 2026 (GLOBE NEWSWIRE) — Brown & Brown, Inc. (NYSE:BRO) (the “Company”) announced its unaudited financial results for the third quarter of 2026.

For the third quarter ended September 30, 2026, the Company achieved:

  • Total revenues of $1.7 billion, increasing $119 million, or 7.4%, compared to the third quarter of the prior year, with growth of Organic Revenue of 1.2% and growth of Organic Revenue with Contingents of 1.5%.
  • Income before income taxes of $320 million, increasing 2.9%, with Income Before Income Taxes Margin of 18.6%, compared to 19.4% in the third quarter of the prior year.
  • EBITDAC – Adjusted of $597 million, increasing 1.7%, with EBITDAC Margin – Adjusted of 34.6%, compared to 36.6% in the third quarter of the prior year.
  • Net income attributable to the Company of $240 million, increasing $13 million, or 5.7%, compared to the third quarter of the prior year.
  • Diluted net income per share of $0.67, a decrease of 1.5%, with Diluted Net Income Per Share – Adjusted increasing to $1.07, or 1.9%, each compared to the third quarter of the prior year.

For the nine months ended September 30, 2026, the Company achieved:

  • Total revenues of $5.3 billion, increasing $1.0 billion, or 23.4%, compared to the same period in 2025, with growth of Organic Revenue of 0.3% and growth of Organic Revenue with Contingents of 1.5%.
  • Income before income taxes of $1.2 billion, increasing 17.6%, with Income Before Income Taxes Margin of 23.3%, compared to 24.4% in the same period in 2025.
  • EBITDAC – Adjusted of $1.9 billion, increasing 20.9%, with EBITDAC Margin – Adjusted of 36.3%, compared to 37.1% in the same period in 2025.
  • Net income attributable to the Company of $954 million, increasing $164 million, or 20.8%, compared to the same period in 2025.
  • Diluted net income per share of $2.57, flat compared to the same period in 2025, with Diluted Net Income Per Share – Adjusted increasing to $3.52, or 5.7%, compared to the same period in 2025.

J. Powell Brown, president and chief executive officer of the Company, noted, “The third quarter reflected the incredible efforts of our teammates to win more customers in spite of a challenging rate environment. Our capabilities were broadly enhanced by the addition of approximately 5,000 new teammates from Accession, just over a year ago.”

             
Reconciliation of Commissions and Fees
to Organic Revenue and Organic Revenue with Contingents
(in millions, unaudited)

             
    Three Months Ended September 30,     Nine Months Ended September 30,  
    2026     2025     2026     2025  
Commissions and fees   $ 1,700     $ 1,550     $ 5,234     $ 4,183  
Contingents     (80 )     (73 )     (262 )     (161 )
Core commissions and fees   $ 1,620     $ 1,477     $ 4,972     $ 4,022  
Acquisitions     (156 )           (985 )      
Dispositions           (13 )           (20 )
Foreign Currency Translation           (1 )           19  
Litigation-Related Impact           (16 )           (44 )
Organic Revenue   $ 1,464     $ 1,447     $ 3,987     $ 3,977  
Organic Revenue growth     17             10        
Organic Revenue growth %     1.2 %           0.3 %      
                         
Organic Contingents   $ 79     $ 73     $ 213     $ 161  
Organic Revenue with Contingents     1,543       1,520       4,200       4,138  
Organic Revenue with Contingents growth   $ 23           $ 62        
Organic Revenue with Contingents growth %     1.5 %           1.5 %      
                             

See information regarding non-GAAP measures presented later in this press release.

                         
Reconciliation of Diluted Net Income Per Share to
Diluted Net Income Per Share – Adjusted
(unaudited)

                         
    Three Months Ended
September 30,
    Change     Nine Months Ended
September 30,
    Change  
    2026     2025     $     %     2026     2025     $     %  
Diluted net income per share(1)   $ 0.67     $ 0.68     $ (0.01 )     (1.5 %)   $ 2.57     $ 2.57     $ —       (— %)
Change in estimated acquisition earn-out payables     0.06       0.02       0.04             (0.02 )     0.04       (0.06 )      
(Gain)/loss on disposal     —       —       —             —       —       —        
Acquisition/Integration Costs     0.09       0.13       (0.04 )           0.21       0.22       (0.01 )      
Amortization     0.25       0.20       0.05             0.76       0.48       0.28        
Mark-to-market of escrow liability(2)     —       0.02       (0.02 )           —       0.02       (0.02 )      
Diluted Net Income Per Share – Adjusted   $ 1.07     $ 1.05     $ 0.02       1.9 %   $ 3.52     $ 3.33     $ 0.19       5.7 %
                                                                 

(1) The calculation of diluted net income per share for the three and nine months ended September 30, 2026 (a) excludes the mark-to-market of escrow liability and (b) includes the escrowed shares within the Company’s diluted weighted average number of shares, in each case in accordance with Accounting Standards Codification Topic 260 — Earnings Per Share (“ASC 260”), which requires this treatment in periods where the combined effect of these adjustments is accretive to earnings.

(2) No adjustment for the mark-to-market of escrow liability was made to Diluted Net Income Per Share – Adjusted for the three or nine months ended September 30, 2026 as the calculation of diluted net income per share for these periods already excludes the mark-to-market of escrow liability in accordance with ASC 260.

See information regarding non-GAAP measures presented later in this press release.

             
Reconciliation of Income Before Income Taxes to EBITDAC and
EBITDAC – Adjusted and Income Before Income Taxes Margin(1) to
EBITDAC Margin and EBITDAC Margin – Adjusted
(in millions, unaudited)

             
    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2026     2025(2)     2026     2025(2)  
Total revenues   $ 1,725     $ 1,606     $ 5,302     $ 4,295  
Income before income taxes   $ 320     $ 311     $ 1,235     $ 1,050  
Income Before Income Taxes Margin(1)     18.6 %     19.4 %     23.3 %     24.4 %
Amortization     110       93       337       196  
Depreciation     18       14       53       37  
Interest     100       100       299       197  
Change in estimated acquisition earn-out payables     27       11       (7 )     18  
EBITDAC   $ 575     $ 529     $ 1,917     $ 1,498  
EBITDAC Margin     33.3 %     32.9 %     36.2 %     34.9 %
(Gain)/loss on disposal     —       —       —       1  
Acquisition/Integration Costs     36       50       93       87  
Mark-to-market of escrow liability     (14 )     8       (83 )     8  
EBITDAC – Adjusted   $ 597     $ 587     $ 1,927     $ 1,594  
EBITDAC Margin – Adjusted     34.6 %     36.6 %     36.3 %     37.1 %
                                 

(1) “Income Before Income Taxes Margin” is defined as income before income taxes divided by total revenues.

(2) 2025 amounts reflect the positive impact of approximately $29 million and $42 million for the three and nine months ended September 30,2025, respectively, of interest income earned from the proceeds of the Company’s follow-on common stock offering and senior notes issuance in June 2025, held in preparation for the closing of the Company’s acquisition of RSC Topco, Inc.

See information regarding non-GAAP measures presented later in this press release.

             
Brown & Brown, Inc.
Consolidated Statements of Income
(in millions, except per share data; unaudited)
             
    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
REVENUES                        
Commissions and fees   $ 1,700     $ 1,550     $ 5,234     $ 4,183  
Investment and other income     25       56       68       112  
Total revenues     1,725       1,606       5,302       4,295  
EXPENSES                        
Employee compensation and benefits     857       793       2,602       2,116  
Other operating expenses     307       276       866       672  
(Gain)/loss on disposal     —       —       —       1  
Amortization     110       93       337       196  
Depreciation     18       14       53       37  
Interest     100       100       299       197  
Change in estimated acquisition earn-out payables     27       11       (7 )     18  
Mark-to-market of escrow liability     (14 )     8       (83 )     8  
Total expenses     1,405       1,295       4,067       3,245  
Income before income taxes     320       311       1,235       1,050  
Income taxes     79       82       278       251  
Net income before non-controlling interests     241       229       957       799  
Less: Net income attributable to non-controlling interests     1       2       3       9  
Net income attributable to the Company   $ 240     $ 227     $ 954     $ 790  
Net income per share:                        
Basic   $ 0.73     $ 0.68     $ 2.87     $ 2.59  
Diluted   $ 0.67     $ 0.68     $ 2.57     $ 2.57  
Weighted average number of shares outstanding:                        
Basic     325       331       328       302  
Diluted     330       332       334       304  

             
Brown & Brown, Inc.
Consolidated Balance Sheets
(in millions, except per share data, unaudited)
             
    September 30,
2026
    December 31,
2025
 
ASSETS            
Current assets:            
Cash and cash equivalents   $ 1,099     $ 1,079  
Fiduciary cash     2,442       2,471  
Commission, fees, and other receivables     1,515       1,438  
Fiduciary receivables     1,234       1,515  
Reinsurance recoverable     665       647  
Prepaid reinsurance premiums     808       980  
Other current assets     498       484  
Total current assets     8,261       8,614  
Fixed assets, net     389       367  
Operating lease assets     304       269  
Goodwill     15,188       15,087  
Amortizable intangible assets, net     4,468       4,906  
Other assets     838       748  
Total assets   $ 29,448     $ 29,991  
LIABILITIES AND EQUITY            
Current liabilities:            
Fiduciary liabilities   $ 3,676     $ 3,986  
Losses and loss adjustment reserve     687       671  
Unearned premiums     903       1,053  
Accounts payable     709       990  
Accrued expenses and other liabilities     844       875  
Current portion of long-term debt     413       719  
Total current liabilities     7,232       8,294  
Long-term debt less unamortized discount and debt issuance costs     7,346       6,894  
Operating lease liabilities     279       243  
Deferred income taxes, net     937       815  
Other liabilities     1,053       1,172  
Equity:            
Common stock, par value $0.10 per share; authorized 560 shares; issued 359 shares and outstanding 327 shares at 2026, issued 357 shares and outstanding 336 shares at 2025     36       36  
Additional paid-in capital     6,253       6,160  
Treasury stock, at cost 32 shares at 2026 and 21 shares at 2025     (1,604 )     (848 )
Accumulated other comprehensive income     124       210  
Non-controlling interests     18       26  
Retained earnings     7,774       6,989  
Total equity     12,601       12,573  
Total liabilities and equity   $ 29,448     $ 29,991  

       
Brown & Brown, Inc.
Consolidated Statements of Cash Flows
(in millions, unaudited)
       
    Nine Months Ended
September 30,
 
    2026     2025  
Cash flows from operating activities:            
Net income before non-controlling interests   $ 957     $ 799  
Adjustments to reconcile net income before non-controlling interests to net cash provided by operating activities:            
Amortization     337       196  
Depreciation     53       37  
Non-cash stock-based compensation     72       76  
Change in estimated acquisition earn-out payables     (7 )     18  
Mark-to-market of escrow liability     (83 )     8  
Deferred income taxes     158       18  
Net loss on sales/disposals of investments, businesses, fixed assets and customer accounts     —       2  
Payments on acquisition earn-outs in excess of original estimated payables     (42 )     (1 )
Other     10       5  
Changes in operating assets and liabilities, net of effect from acquisitions and divestitures:            
Commissions, fees and other receivables (increase)/decrease     (100 )     (59 )
Reinsurance recoverable (increase)/decrease     (18 )     1,190  
Prepaid reinsurance premiums (increase)/decrease     172       8  
Other assets (increase)/decrease     (87 )     (23 )
Losses and loss adjustment reserve increase/(decrease)     16       (1,188 )
Unearned premiums increase/(decrease)     (153 )     15  
Accounts payable increase/(decrease)     (107 )     (95 )
Accrued expenses and other liabilities increase/(decrease)     (63 )     (41 )
Other liabilities increase/(decrease)     25       41  
Net cash provided by operating activities     1,140       1,006  
Cash flows from investing activities:            
Additions to fixed assets     (77 )     (48 )
Payments for businesses acquired, net of cash acquired     (41 )     (7,659 )
Proceeds from sales of businesses, fixed assets and customer accounts     3       10  
Other investing activities     (10 )     (4 )
Net cash used in investing activities     (125 )     (7,701 )
Cash flows from financing activities:            
Fiduciary receivables and liabilities, net     (14 )     (145 )
Payments on acquisition earn-outs     (199 )     (77 )
Proceeds from long-term debt     —       4,192  
Payments on long-term debt     (34 )     (206 )
Deferred debt issuance costs     (3 )     (37 )
Borrowings on revolving credit facility     225       450  
Payments on revolving credit facility     (50 )     (500 )
Proceeds from issuance of common stock, net of expenses     —       4,315  
Issuances of common stock for employee stock benefit plans     47       43  
Repurchase shares to fund tax withholdings for non-cash stock-based compensation     (30 )     (42 )
Purchase of treasury stock     (750 )     —  
Cash dividends paid     (169 )     (137 )
Other financing activities     (12 )     (5 )
Net cash (used in) provided by financing activities     (989 )     7,851  
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash inclusive of fiduciary cash     (29 )     66  
Net (decrease) increase in cash, cash equivalents and restricted cash inclusive of fiduciary cash     (3 )     1,222  
Cash, cash equivalents and restricted cash inclusive of fiduciary cash at beginning of period     3,815       2,502  
Cash, cash equivalents and restricted cash inclusive of fiduciary cash at end of period   $ 3,812     $ 3,724  
                 

Conference call, webcast and slide presentation

A conference call to discuss the results of the third quarter of 2026 will be held on Tuesday, October 27, 2026, at 8:00 AM (EDT). The Company may refer to a slide presentation during its conference call. You can access the webcast and the slides from the “Investor Relations” section of the Company’s website at bbrown.com.

About Brown & Brown

Brown & Brown, Inc. (NYSE: BRO) is a leading insurance brokerage firm delivering comprehensive and customized insurance solutions and specialization since 1939. With a global presence spanning 700+ locations and a team of approximately 23,000 professionals, we are dedicated to delivering scalable, innovative strategies for our customers at every step of their growth journey. Learn more at BBrown.com.

Forward-looking statements

This press release may contain certain statements relating to future results which are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created by those laws. You can identify these statements by forward-looking words such as “may,” “will,” “should,” “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan” and “continue” or similar words. We have based these statements on our current expectations about potential future events. Although we believe the expectations expressed in the forward-looking statements included in this press release are based upon reasonable assumptions within the bounds of our knowledge of our business, a number of factors could cause actual results to differ materially from those expressed in any forward-looking statements, whether oral or written, made by us or on our behalf. Many of these factors have previously been identified in filings or statements made by us or on our behalf. Important factors which could cause our actual results to differ, possibly materially from the forward-looking statements in this press release include but are not limited to the following items: the Company’s determination as it finalizes its financial results for the third quarter of 2026 that its financial results differ from the current preliminary unaudited numbers set forth herein; risks with respect to the acquisition of RSC Topco, Inc. (“Accession”) (the “Transaction”); the possibility that the anticipated benefits, including any anticipated cost savings and strategies, of the Transaction are not realized when expected or at all; risks related to the financing of the Transaction, including that financing the Transaction resulted in an increase in the Company’s indebtedness; risks relating to the financial information related to Accession; the risk that certain assumptions the Company has made relating to the Transaction prove to be materially inaccurate; risks related to Accession’s business, including underwriting risk in connection with certain captive insurance companies; the inability to hire, retain and develop qualified employees, as well as the loss of any of our executive officers or other key employees; a cybersecurity attack or any other interruption in information technology and/or data security that may impact our operations or the operations of third parties that support us; acquisition-related risks that could negatively affect the success of our growth strategy, including the possibility that we may not be able to successfully identify suitable acquisition candidates, complete acquisitions, successfully integrate acquired businesses into our operations and expand into new markets; risks related to our international operations, which may result in additional risks or require more management time and expense than our domestic operations to achieve or maintain profitability; the requirement for additional resources and time to adequately respond to dynamics resulting from rapid technological change, including the increasing use of artificial intelligence and robotic processing automation; the loss of or significant change to any of our insurance company or intermediary relationships, which could result in loss of capacity to write business, additional expense, loss of market share or material decrease in our commissions; the effect of natural disasters on our Contingents, insurer capacity or claims expenses within our capitalized captive insurance facilities; adverse economic conditions, political conditions, outbreaks of war, disasters, or regulatory changes in states or countries where we have a concentration of our business; the inability to maintain our culture or a significant change in management, management philosophy or our business strategy; fluctuations in our commission revenue as a result of factors outside of our control; the effects of significant or sustained inflation or higher interest rates; claims expense resulting from the limited underwriting risk associated with our participation in captive insurance facilities; risks associated with our automobile and recreational vehicle finance and incentives dealer services (“F&I”) businesses; changes in, or the termination of, certain programs administered by the U.S. federal government from which we derive revenues; the limitations of our system of disclosure and internal controls and procedures in preventing errors or fraud, or in informing management of all material information in a timely manner; our reliance on vendors and other third parties to perform key functions of our business operations and provide services to our customers; the significant control certain shareholders have; changes in data privacy and protection laws and regulations or any failure to comply with such laws and regulations; improper disclosure of confidential information; our ability to comply with non-U.S. laws, regulations and policies; the potential adverse effect of certain actual or potential claims, regulatory actions or proceedings on our businesses, results of operations, financial condition or liquidity; uncertainty in our business practices and compensation arrangements with insurance carriers due to potential changes in regulations; regulatory changes that could reduce our profitability or growth by increasing compliance costs, technology compliance, restricting the products or services we may sell, the markets we may enter, the methods by which we may sell our products and services, or the prices we may charge for our services and the form of compensation we may accept from our customers, carriers and third parties; increasing scrutiny and changing laws or competing expectations from regulators, investors and customers with respect to our environmental, social and governance practices and disclosure; a decrease in demand for liability insurance as a result of tort reform legislation; our failure to comply with any covenants contained in our debt agreements; the possibility that covenants in our debt agreements could prevent us from engaging in certain potentially beneficial activities; fluctuations in foreign currency exchange rates; a downgrade to our corporate credit rating, the credit ratings of our outstanding debt or other market speculation; future sales or other dilution of our equity could adversely affect the market price of our common stock; changes in the U.S.-based credit markets that might adversely affect our business, results of operations and financial condition; changes in current U.S. or global economic conditions, including an extended slowdown in the markets in which we operate; disintermediation within the insurance industry, including increased competition from insurance companies, technology companies and the financial services industry, as well as the shift away from traditional insurance markets; conditions that result in reduced insurer capacity; quarterly and annual variations in our commissions that result from the timing of policy renewals and the net effect of new and lost business production; intangible asset risk, including the possibility that our goodwill may become impaired in the future; changes in our accounting estimates and assumptions; other risks and uncertainties as may be detailed from time to time in our public announcements and Securities and Exchange Commission (“SEC”) filings; and other factors that the Company may not have currently identified or quantified. Assumptions as to any of the foregoing, and all statements, are not based upon historical fact, but rather reflect our current expectations concerning future results and events. Forward-looking statements that we make or that are made by others on our behalf are based upon a knowledge of our business and the environment in which we operate, but because of the factors listed above, among others, actual results may differ from those in the forward-looking statements. Consequently, these cautionary statements qualify all of the forward-looking statements we make herein. We cannot assure you that the results or developments anticipated by us will be realized, or even if substantially realized, that those results or developments will result in the expected consequences for us or affect us, our business or our operations in the way we expect. We caution readers not to place undue reliance on these forward-looking statements. All forward-looking statements made herein are made only as of the date of this press release, and the Company does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which the Company hereafter becomes aware.

Non-GAAP supplemental financial information

This press release contains references to “non-GAAP financial measures” as defined in SEC Regulation G, consisting of Organic Revenue, Organic Revenue with Contingents, EBITDAC, EBITDAC Margin, EBITDAC – Adjusted, EBITDAC Margin – Adjusted and Diluted Net Income Per Share – Adjusted. We present these measures because we believe such information is of interest to the investment community and because we believe they provide additional meaningful methods to evaluate the Company’s operating performance from period to period on a basis that may not be otherwise apparent on a GAAP basis due to the impact of certain items that have a high degree of variability, that we believe are not indicative of ongoing performance and that are not easily comparable from period to period. This non-GAAP financial information should be considered in addition to, not in lieu of, GAAP information as of the relevant date. Consistent with Regulation G, a description of such information is provided below, and tabular reconciliations of such items to our most directly comparable GAAP information can be found within this press release as well as in our periodic filings with the SEC.

We view Organic Revenue and Organic Revenue growth (including Organic Revenue with Contingents and its growth) as important indicators when assessing and evaluating our performance on a consolidated basis and for each of our two segments, because they allow us to determine a comparable, but non-GAAP, measurement of revenue growth that is associated with the revenue sources that were a part of our business in both the current and prior year and that are expected to continue in the future. In addition, we believe Diluted Net Income Per Share – Adjusted provides a meaningful representation of our operating performance and improves the comparability of our results between periods by excluding the impact of the change in estimated acquisition earn-out payables, the impact of amortization of intangible assets and certain other non-recurring or infrequently occurring items. We also view EBITDAC, EBITDAC – Adjusted, EBITDAC Margin and EBITDAC Margin – Adjusted as important indicators when assessing and evaluating our performance, as they present more comparable measurements of our operating margins in a meaningful and consistent manner. As disclosed in our most recent proxy statement, we use Organic Revenue growth, Diluted Net Income Per Share – Adjusted and EBITDAC Margin – Adjusted as key performance metrics for our short-term and long-term incentive compensation plans for executive officers and other key employees.

Non-GAAP Revenue Measures

  • Organic Revenue is our core commissions and fees less: (i) the core commissions and fees earned for the first twelve months by newly acquired operations; (ii) divested business (core commissions and fees generated from offices, books of business or niches sold or terminated during the comparable period); (iii) Foreign Currency Translation (as defined below) and (iv) the Litigation-Related Impact. The term “core commissions and fees” excludes profit-sharing contingent commissions (“Contingents”); and therefore, represents the revenues earned directly from specific insurance policies sold and specific fee-based services rendered. Growth of Organic Revenue can be expressed as a dollar amount or a percentage rate.
  • Organic Revenue with Contingents is Organic Revenue plus Organic Contingents (as defined below). Growth of Organic Revenue with Contingents can be expressed as a dollar amount or a percentage rate.

Non-GAAP Earnings Measures

  • EBITDAC is defined as income before interest, income taxes, depreciation, amortization and the change in estimated acquisition earn-out payables.
  • EBITDAC Margin is defined as EBITDAC divided by total revenues.
  • EBITDAC – Adjusted is defined as EBITDAC, excluding (i) (gain)/loss on disposal (as defined below), (ii) Acquisition/Integration Costs (as defined below) and (iii) mark-to-market of escrow liability (as defined below).
  • EBITDAC Margin – Adjusted is defined as EBITDAC – Adjusted divided by total revenues.
  • Diluted Net Income Per Share – Adjusted is defined as diluted net income per share, excluding the after-tax impact of (i) the change in estimated acquisition earn-out payables, (ii) (gain)/loss on disposal, (as defined below), (iii) Acquisition/Integration Costs (as defined below), (iv) mark-to-market of escrow liability (as defined below) in periods wherein the effect of mark-to-market of escrow liability is not dilutive to the Company’s earnings and, therefore, not already excluded from the calculation of diluted net income per share in accordance with ASC 260, and (v) amortization.

Definitions Related to Certain Components of Non-GAAP Measures

  • “Acquisition/Integration Costs” means the acquisition and integration costs (e.g., costs associated with regulatory filings; costs for third-party professional services, including legal, accounting, consulting, financial advisory and due diligence; costs and fees associated with entry into the bridge financing commitment; costs of integrating or streamlining processes and information technology systems, including data migration and system integration; costs associated with optimizing vendor agreements and leased office space, including exit costs related to location combinations; and employment-related costs, including severance payments, costs associated with the transition of certain legacy compensation programs, retention-related compensation expenses, and incentive payments) arising out of our acquisition of Accession and acquisitions previously completed by Accession, which are not considered to be normal, recurring or part of ongoing operations.
  • “Foreign Currency Translation” means the period-over-period impact of foreign currency translation, which is calculated by applying current-year foreign exchange rates to the various functional currencies in our business to our reporting currency of US dollars for the same period in the prior year.
  • “(Gain)/loss on disposal” is a caption on our consolidated statements of income which reflects net proceeds received as compared to the net book value related to sales of books of business and other divestiture transactions.
  • “Mark-to-market of escrow liability” is a caption on our consolidated statements of income which reflects the non-cash change in the fair value associated with certain shares of the Company’s common stock held in escrow. The change is driven by fluctuations in our stock price between the beginning of the period and the end of the period. These escrowed shares represent a portion of the merger consideration payable in connection with our acquisition of Accession. The escrowed shares secure certain indemnification obligations of the Accession equity holders related to businesses that are in run-off or discontinued.
  • “Litigation-Related Impact” means the core commissions and fees attributable to (i) the loss of specifically identified customer accounts and (ii) new business generated in the prior year by certain former employees, in each case in connection with the conduct of a competitor that is the subject of pending litigation in multiple jurisdictions.
  • “Organic Contingents” are Contingents, less (i) Contingents earned for the first twelve months by newly acquired stand-alone operations and (ii) Contingents earned from divested stand-alone operations (Contingents generated from stand-alone operations sold or terminated during the comparable period).

Our industry peers may provide similar supplemental non-GAAP information with respect to one or more of these measures, although they may not use the same or comparable terminology and may not make identical adjustments and, therefore comparability may be limited. This supplemental non-GAAP financial information should be considered in addition to, and not in lieu of, the Company’s condensed consolidated financial statements.

For more information:

R. Andrew Watts
Chief Financial Officer
(386) 239-5770

WHITE SULPHUR SPRINGS, Mont., Oct. 26, 2026 (GLOBE NEWSWIRE) — Sandfire Resources America Inc. (“Sandfire America” or the “Company”) (TSXV:SFR) announces that its Board of Directors (the “Board”) has initiated a review of strategic alternatives (“Strategic Review”) to advance the Black Butte Project and maximize value for all shareholders. During the Strategic Review, the Board will analyze and evaluate potential strategic alternatives, which may include, but is not limited to, a sale of the Company. In connection with the Strategic Review, the Company has established a special committee comprised of independent directors (the “Special Committee”) to oversee the Strategic Review.

The Company is publicly announcing the Strategic Review as part of its value-maximization strategy, while management of the Company continues to implement the Company’s current business plan in seeking to achieve the Company’s key objectives. The Company and the Board have not set a timetable for the conclusion of the Strategic Review. The Company does not intend to disclose developments with respect to the Strategic Review unless and until the Board has approved a specific transaction or otherwise determines that disclosure is appropriate or required by applicable securities law.

Sandfire Resources Limited, the Company’s largest shareholder, has expressed its support for the Strategic Review and its intention to continue supporting the Company in executing its current business plan.

In connection with the Strategic Review, the Company has engaged RBC Capital Markets as its financial advisor and the Special Committee has engaged Fasken Martineau DuMoulin LLP as its legal advisor.

The Company cautions that the engagement of financial and legal advisors should not be viewed as an indication that any specific action, transaction or agreement will be pursued. There can be no assurances that the Strategic Review will result in any specific action, transaction, or agreement, or if a transaction is undertaken, as to its timing, completion or terms.

Contact Information:
Sandfire Resources America Inc.
Nancy Schlepp, VP of Communications and Government Relations
Mobile: 406-224-8180
Office: 406-547-3466
Email: nschlepp@sandfireamerica.com

FORWARD-LOOKING INFORMATION

Certain information in this press release contains forward-looking information. This information is based on management’s reasonable assumptions and beliefs in light of the information currently available to the Company and is made as of the date of this press release. Information regarding expectations of future results, performance, achievements, prospects or opportunities or the markets in which the Company operates is forward-looking information. The forward-looking information in this press release include statements regarding the Strategic Review, the possibility of a transaction involving the Company, the continued implementation of the Company’s business plan, the ability to achieve value-maximization, and the support of Sandfire Resources Limited for the Strategic Review and the Company’s current business plan.

Statements containing forward-looking information are not facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances. Forward-looking information is based on assumptions that management considers reasonable given the information currently available. Actual results may differ materially from those expressed or implied by the forward-looking information. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially, including but not limited to: the Strategic Review and the timing thereof; whether the Strategic Review will result in the Company undertaking any transaction and, if so, the terms, timing and completion thereof and any value resulting therefrom; general economic, market and business conditions; changes in law, regulation or policy; competitive dynamics in the industry in which the Company operates; the Company’s ability to implement its current business plan; the Company’s ability to retain key personnel; and other factors, many of which are beyond the control of the Company, as described in the documents filed with the Canadian securities regulatory authorities from time to time and which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

Readers are urged to consider the uncertainties, risks and assumptions carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information. The Company has no intention, and undertakes no obligation, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

WHITE SULPHUR SPRINGS, Mont., Oct. 26, 2026 (GLOBE NEWSWIRE) — Sandfire Resources America Inc. (“Sandfire America” or the “Company”) (TSXV:SFR) announces that its Board of Directors (the “Board”) has initiated a review of strategic alternatives (“Strategic Review”) to advance the Black Butte Project and maximize value for all shareholders. During the Strategic Review, the Board will analyze and evaluate potential strategic alternatives, which may include, but is not limited to, a sale of the Company. In connection with the Strategic Review, the Company has established a special committee comprised of independent directors (the “Special Committee”) to oversee the Strategic Review.

The Company is publicly announcing the Strategic Review as part of its value-maximization strategy, while management of the Company continues to implement the Company’s current business plan in seeking to achieve the Company’s key objectives. The Company and the Board have not set a timetable for the conclusion of the Strategic Review. The Company does not intend to disclose developments with respect to the Strategic Review unless and until the Board has approved a specific transaction or otherwise determines that disclosure is appropriate or required by applicable securities law.

Sandfire Resources Limited, the Company’s largest shareholder, has expressed its support for the Strategic Review and its intention to continue supporting the Company in executing its current business plan.

In connection with the Strategic Review, the Company has engaged RBC Capital Markets as its financial advisor and the Special Committee has engaged Fasken Martineau DuMoulin LLP as its legal advisor.

The Company cautions that the engagement of financial and legal advisors should not be viewed as an indication that any specific action, transaction or agreement will be pursued. There can be no assurances that the Strategic Review will result in any specific action, transaction, or agreement, or if a transaction is undertaken, as to its timing, completion or terms.

Contact Information:
Sandfire Resources America Inc.
Nancy Schlepp, VP of Communications and Government Relations
Mobile: 406-224-8180
Office: 406-547-3466
Email: nschlepp@sandfireamerica.com

FORWARD-LOOKING INFORMATION

Certain information in this press release contains forward-looking information. This information is based on management’s reasonable assumptions and beliefs in light of the information currently available to the Company and is made as of the date of this press release. Information regarding expectations of future results, performance, achievements, prospects or opportunities or the markets in which the Company operates is forward-looking information. The forward-looking information in this press release include statements regarding the Strategic Review, the possibility of a transaction involving the Company, the continued implementation of the Company’s business plan, the ability to achieve value-maximization, and the support of Sandfire Resources Limited for the Strategic Review and the Company’s current business plan.

Statements containing forward-looking information are not facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances. Forward-looking information is based on assumptions that management considers reasonable given the information currently available. Actual results may differ materially from those expressed or implied by the forward-looking information. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially, including but not limited to: the Strategic Review and the timing thereof; whether the Strategic Review will result in the Company undertaking any transaction and, if so, the terms, timing and completion thereof and any value resulting therefrom; general economic, market and business conditions; changes in law, regulation or policy; competitive dynamics in the industry in which the Company operates; the Company’s ability to implement its current business plan; the Company’s ability to retain key personnel; and other factors, many of which are beyond the control of the Company, as described in the documents filed with the Canadian securities regulatory authorities from time to time and which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

Readers are urged to consider the uncertainties, risks and assumptions carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information. The Company has no intention, and undertakes no obligation, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

HOUSTON, Oct. 26, 2026 (GLOBE NEWSWIRE) — Microvast Holdings, Inc. (NASDAQ: MVST), (“Microvast” or the “Company”), today announced that it will issue a press release reporting its consolidated financial results for the third quarter of 2026 after market close on Monday, November 9, 2026.

Following the earnings press release, Microvast management will host a webcast and earnings conference call at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) to discuss the business results and outlook. The webcast will be accessible from the Events & Presentations tab of Microvast’s investor relations website at https://ir.microvast.com. A replay will be available following the conclusion of the event.

About Microvast

Microvast strives to be a global leader in advanced battery technologies, with a portfolio of more than 890 patents. Founded in Texas in 2006 and headquartered in Houston, the company has spent two decades engineering cutting-edge battery systems that are intended to power a cleaner future. Microvast stands as a trusted global partner with the mission to provide the high-performance solutions required for today’s electrification needs.

For more information, please visit www.microvast.com or follow us on LinkedIn (@microvast).

Contact

Investor Relations
ir@microvast.com 

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.